Metraipolis › archive › dc_7137d97ba237

Targeted Biocatalyst Design for Asymmetric Citalopram Conversion in a Membrane Reactor — Europe PMC PMID:41304833

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41304833
DOI
10.3390/pharmaceutics17111497
License (as archived)
solo-consultazione
Archived
2026-11-08T10:50:41.484Z
SHA-256 of the archived text
4d219aca5d7079191e1fb65440ea2354ed5289f1e4ec624571c979d4c1126126
Stable URL of this page
https://metraipolis.com/documento/dc_7137d97ba237

How to cite

Targeted Biocatalyst Design for Asymmetric Citalopram Conversion in a Membrane Reactor — Europe PMC PMID:41304833 — Europe PMC (en), https://europepmc.org/article/MED/41304833 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7137d97ba237 (Metraipolis archive dc_7137d97ba237, sha256 4d219aca5d7079191e1fb65440ea2354ed5289f1e4ec624571c979d4c1126126)
BibTeX
@misc{dc7137d97ba237,
  title = {Targeted Biocatalyst Design for Asymmetric Citalopram Conversion in a Membrane Reactor — Europe PMC PMID:41304833},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41304833},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7137d97ba237; sha256 4d219aca5d7079191e1fb65440ea2354ed5289f1e4ec624571c979d4c1126126},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41304833. Agents can read the archived copy with the MCP tool read_document.